Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Preveceutical Medical Inc C.PREV

Alternate Symbol(s):  PRVCF

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.


CSE:PREV - Post by User

Preveceutical Medical Inc > Still loading
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(200)
•••
Comment by itwillgo1on Jul 29, 2020 11:22pm
80 Views
Post# 31341494

RE:RE:RE:Still loading

RE:RE:RE:Still loadingIf I knew the answer to the question why would I ask?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities